Objective: To analyze the relationship between Factor V Leiden mutation, protein S, protein C and anticoagulation for cerebral venous sinus thrombosis (CVST). Methods: A total of 103 patients with cerebral venous sinus thrombosis in the Third People's Hospital of Bengbu from February 2018 to February 2022 were selected as the research subjects. 103 patients were divided into the observation group A (n=33), observation group B (n=34) and control group (n =36) according to DNA and ELISA detection results. Thromboelastography (TEG) parameters, INR and APTT levels of the three groups were recorded on the 3rd, 7th and 15th days of anticoagulant treatment, the collected data was analyzed to study the relationship between Factor V Leiden mutation, protein S, protein C and anticoagulation for cerebral venous sinus thrombosis. Results: On the 3rd, 7th and 15th days of anticoagulant treatment, no obvious prolongation of coagulation reaction (R) or blood clot kinetics (K) was found in the observation group A. Maximal amplitude (MA) was not significantly decreased, INR level was not significantly increased, and APTT level was not significantly prolonged in the observation group A. Comparing with the control group and observation group B, the differences were statistically significant (P＜0.05). While the prolongation of coagulation reaction (R) and blood clot formation in observation group B were only statistically different with the control group on the 3rd days of anticoagulation treatment (P＜0.05). On the 7th and 15th days of anticoagulant treatment, significant prolongation of coagulation reaction (R) and blood clot formation (K) was found in the observation group B. Maximal clot strength (MA) was significantly decreased, INR level was significantly increased, and APTT level was significantly prolonged in the observation group B. However, the differences were not statistically significant comparing with the control group (P＞0.05). Conclusion: The effect of anticoagulant therapy is poor for CVST patients with Factor V Leiden mutation, but better for CVST patients with low level of protein S and protein C, which could get the best effect for patients without Factor V Leiden mutation or low level of protein S and protein C. Leiden mutation of V factor and low level of protein S and C are correlated with the anticoagulant effectiveness in CVST.
LU Feihu
,
YU Xue
. Correlation between Factor V Leiden mutation, protein S, protein C and anticoagulation for cerebral venous sinus thrombosis[J]. Journal of Baotou Medical College, 2022
, 38(11)
: 80
-85
.
DOI: 10.16833/j.cnki.jbmc.2022.11.016
[1] Kalita J, Misra UK, Singh RK. Do the risk factors determine the severity and outcome of cerebral venous sinus thrombosis[J].Transl Stroke Res, 2018, 9(6):575-581.
[2] Gayathri K, Ramalingam PK, Santhakumar R, et al. Cerebral sinus venous thrombosis as a rare complication of primary varicella zoster virus infection[J].J Assoc Physicians India, 2016, 64(7):74-76.
[3] 冯六连, 李儒佑. 血小板反应蛋白-1在复发性流产患者绒毛膜组织中的表达及其价值探讨[J].现代中西医结合杂志,2019,28(14):1533-1536.
[4] 王杏,盛广影,张威,等.家族性蛋白C与蛋白S基因联合杂合突变家系的基因变异特点与临床特征分析[J].中国实验血液学杂志,2021,29(2):591-595.
[5] 黄启俊,傅应云.蛋白C/蛋白S缺乏肺血栓栓塞症中血小板聚集功能的研究进展[J].临床肺科杂志,2019,24(4):751-754.
[6] Daley MJ, Enright Z, Nguyen J, et al. Adenosine diphosphate platelet dysfunction on thromboelastogram is independently associated with increased morality in traumatic brain injury[J].Eur J Trauma Emerg Surg, 2017, 43(1):105-111.
[7] 白重阳,董轲.急性脑梗死患者血栓弹力图与凝血功能的关系[J].海南医学,2020,31(15):1923-1926.
[8] Wang Z, Li J, Cao Q, et al. Comparison between thromboelastography and conventional coagulation tests in surgical patients with localized prostate cancer[J].Clin Appl Thromb Hemost, 2018, 24(5):755-763.
[9] 吴剑锋.复发性自然流产患者血浆D-二聚体、抗凝血酶Ⅲ和蛋白C检测的临床意义[J].现代检验医学杂志,2018,33(4):112-114.
[10] 范一木.《颅内静脉和静脉窦血栓形成诊治的中国专家共识》解读[J].中国现代神经疾病杂志,2016,16(12):822-825.
[11] 仝瑞龙.利伐沙班治疗老年非瓣膜性心房颤动患者的有效性及安全性分析 [J].中国实用医药,2020,15(3):4-6.
[12] Potpara TS, Ferro CJ, Lip GYH. Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction[J].Nat Rev Nephrol, 2018, 14(5):337-351.
[13] Mannstadt M, Clarke BL, Bilezikian JP, et al. Safety and efficacy of 5 years of treatment with recombinant human parathyroid hormone in adults with hypoparathyroidism[J].J Clin Endocrinol Metab, 2019, 104(11):5136-5147.
[14] 张华弟,王楚林.利伐沙班与华法林对房颤患者的抗凝有效性及安全性比较[J].中外医学研究,2021,19(19):4-6.
[15] 许俊旭,王振贤,王聪.海口市两家医院2010-2017年肺血栓栓塞症流行病学及危险因素分析[J].中国热带医学,2018,22(2):166-169.
[16] 韩锐,李秀.联合检测活化蛋白C-蛋白C抑制物复合物、D-二聚体对静脉血栓栓塞症的诊断价值[J].临床肺科杂志,2017,22(3):421-423.
[17] Timp JF, Braekkan SK, Lijfering WM, et al. Prediction of recurrent venous thrombosis in all patients with a first venous thrombotic event: The Leiden Thrombosis Recurrence Risk Prediction model (L-TRRiP)[J].PLoS Med, 2019, 16(10):e1002883.
[18] 骏达,梁凌云,武欣.血管生成素和血小板反应蛋白在复发性流产(RSA)患者绒毛组织中的表达及其与血管生成的关系[J].复旦学报(医学版),2020,47(4):551-553,559.
[19] Tran HA, Gibbs H, Merriman E, et al. New guidelines from the Thrombosis and Haemostasis Society of Australia and New Zealand for the diagnosis and management of venous thromboembolism[J].Med J Aust, 2019, 210(5):227-235.
[20] 施林领,伯乐,李海燕,等.复发性流产中基质金属蛋白酶的调控机制研究[J].中华生殖与避孕杂志,2019,39(1):17-21.
[21] 高波,周荣富,欧阳建.蛋白C缺陷症四例报告及基因分析[J].中华血液学杂志,2016,37(11):966-970.
